Safety, Tolerability and Blood Sampling of GSK3923868 Administered Via Dry Powder Inhaler to Healthy Participants of Chinese, Japanese and European Ancestry

Exclusion Criteria

• •History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data
• •Serum Alanine transaminase (ALT) and Aspartate Aminotransferase (AST) above Upper limit of normal (ULN)
• •Total Bilirubin above ULN (isolated bilirubin above ULN is acceptable if total bilirubin is fractionated and direct bilirubin less than \[\<\] 35 percent \[%\])
• •Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
• •QTcF greater than (\>) 450 milliseconds (msec) at Screening visit based on the average of triplicate ECGs
• •Past or intended use of over-the-counter or prescription medication, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) before the first dose of study treatment, unless in the opinion of the investigator and the GSK Medical Monitor (if necessary), the medication will not interfere with the study procedures or compromise participant safety
• •Recent donation of blood or blood products such that participation in this study would result in loss of blood in excess of 500 mL within a 60-day period.
• •Exposure to more than 4 new chemical or molecular entities within 12 months before the first dosing day
• •Current enrolment or past participation in a clinical trial and has received an investigational product within the following time period before the first dosing day in this study: 45 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer)
• •FEV1 \<80% predicted normal value at Screening
• •Presence of hepatitis B surface antigen at screening or within 3 months prior to first dose of study intervention
• •Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention
• •Positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention
• •Positive pre-study drug/alcohol screen
• •Positive HIV antibody test
• •Current or history of drug abuse
• •Current or previous use of tobacco- or nicotine-containing products (e.g. cigarettes, nicotine patches or electronic devices) within 6 months before screening and/or have a smoking pack history of \>5 pack years
• •Positive urine cotinine test indicative of recent smoking at Screening or admission to the clinical research unit
• •History of regular alcohol consumption within 6 months prior to the study defined as: An average weekly intake of \>14 units for males and females
• •Sensitivity to the study intervention or components thereof, or drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study